ANSWER: B

Rationale:

Acute withdrawal of dopaminergic therapy in Parkinson's disease carries a risk of severe motor deterioration and, in rare cases, a potentially life-threatening parkinsonism-hyperpyrexia syndrome resembling neuroleptic malignant syndrome. Maintaining dopaminergic coverage through a 36-hour perioperative NPO period is therefore a genuine clinical priority, not an optional convenience. Rotigotine transdermal patch is the ideal solution because it is the only non-ergot dopamine agonist available as a transdermal formulation. Drug is delivered continuously through the skin at a constant rate over 24 hours, completely bypassing gastrointestinal absorption and oral administration. The patch can be applied the day before surgery, maintained through the procedure and recovery period, and continued postoperatively until oral medications resume — providing uninterrupted dopaminergic stimulation without any enteral requirement. Option B is correct.

• Option A: Option A is incorrect because holding all dopaminergic therapy for 36 hours is not appropriate perioperative management for an established PD patient; acute medication withdrawal can precipitate severe motor deterioration and carries the risk of parkinsonism-hyperpyrexia syndrome, which has significant morbidity and mortality.
• Option C: Option C is incorrect because while nasogastric administration of crushed pramipexole is a theoretical option, it requires placement of a nasogastric tube — an invasive intervention not routinely indicated for perioperative medication management — and is far less practical than the established non-invasive transdermal alternative.
• Option D: Option D is incorrect because levodopa-carbidopa oral dissolving tablets are designed for rapid oral mucosal disintegration followed by gastrointestinal absorption — they are not sublingually bioavailable in a meaningful way and do not represent an established perioperative strategy for NPO patients.
• Option E: Option E is incorrect because continuous subcutaneous apomorphine infusion is a specialized therapy for advanced PD with refractory motor fluctuations, requiring pre-established titration, nursing infrastructure, and patient training; initiating it perioperatively in a patient without an established infusion regimen is not appropriate, and rotigotine patch is the correct and widely recommended perioperative dopaminergic maintenance strategy.

ANSWER: E

Rationale:

Pramipexole is eliminated almost entirely by renal excretion as unchanged drug, and its clearance is directly proportional to creatinine clearance. A CrCl of 24 mL/min represents severe renal impairment, at which the maximum daily dose that can be given safely is substantially lower than the dose appropriate for normal or near-normal renal function. The patient's resumed regimen of 1 mg three times daily — the dose appropriate for his preoperative CrCl of 54 mL/min — therefore far exceeds the ceiling supported by his current renal function and carries a significant accumulation risk. The dose must be reduced promptly to the level indicated for his current CrCl per the prescribing information, with close monitoring and upward retitration as CrCl recovers over the anticipated 2 to 4 weeks. Option E is correct.

• Option A: Option A is incorrect because pramipexole's therapeutic effect is concentration-dependent — drug accumulation in renal impairment at doses appropriate for normal renal function produces dose-related toxicity including nausea, somnolence, hallucinations, and orthostatic hypotension; receptor occupancy does not remain fixed regardless of plasma concentration.
• Option B: Option B is incorrect because dose increase is not appropriate in renal impairment; acute kidney injury does not impair striatal dopamine receptor sensitivity requiring compensatory dose escalation — the opposite adjustment is required.
• Option C: Option C is incorrect because a CrCl of 24 mL/min is not an absolute contraindication to pramipexole; the drug can be used in this range with mandatory dose reduction, and discontinuation followed by ropinirole initiation is not the required management step.
• Option D: Option D is incorrect because a modest reduction to 0.75 mg three times daily is insufficient for a CrCl of 24 mL/min; this value represents severe, not mild, renal impairment and requires a substantial reduction well below the resumed dose, not a small downward adjustment.

ANSWER: A

Rationale:

Metoclopramide is a dopamine D2 receptor antagonist that crosses the blood-brain barrier and blocks central D2 receptors in the striatum. In Parkinson's disease, antiparkinsonian therapy — whether levodopa or a dopamine agonist — depends on dopaminergic activation of striatal D2 receptors. Metoclopramide directly opposes this mechanism, causing acute worsening of motor function in PD patients and potentially precipitating severe rigidity, akinesia, and in some cases a neuroleptic malignant syndrome-like state. This makes metoclopramide specifically contraindicated in all PD patients regardless of route or dose. The appropriate antiemetic alternative in this context is domperidone — a peripherally acting D2 antagonist that does not cross the blood-brain barrier — if available (it is not commercially available in the United States). When domperidone is unavailable, ondansetron is an acceptable alternative for postoperative nausea in this patient, since the ondansetron-apomorphine QTc interaction applies specifically to patients on concurrent apomorphine therapy, which this patient is not receiving. Option A is correct.

• Option B: Option B is incorrect because metoclopramide does not inhibit aromatic amino acid decarboxylase; carbidopa is the decarboxylase inhibitor co-administered therapeutically with levodopa, and metoclopramide's mechanism is dopamine D2 receptor antagonism, not enzyme inhibition.
• Option C: Option C is incorrect because metoclopramide is not a clinically significant CYP1A2 inhibitor and does not affect pramipexole plasma concentrations through enzyme inhibition; furthermore, pramipexole is not a CYP1A2 substrate — it is renally eliminated as unchanged drug.
• Option D: Option D is incorrect because metoclopramide's mechanism is D2 receptor antagonism; while it also has 5-HT4 agonist prokinetic activity, it does not activate 5-HT3 receptors, and direct inhibition of nigrostriatal dopamine release through a serotonergic mechanism is not an established pharmacological effect of metoclopramide.
• Option E: Option E is incorrect because while metoclopramide does have some alpha-adrenergic activity at higher doses, its contraindication in PD is based on central D2 receptor blockade worsening motor function, not on alpha-adrenergic-mediated orthostatic hypotension.

ANSWER: C

Rationale:

The correct transition method from rotigotine transdermal to oral pramipexole is to administer the first oral dose and remove the patch simultaneously. This approach ensures continuous dopaminergic coverage — there is no gap between formulations — while preventing a period of double-dosing that would occur if the patch were left in place after oral therapy resumed. Rotigotine continues delivering drug through the skin until the patch is physically removed; leaving it in place alongside oral pramipexole produces combined exposure from both agents. Regarding the dose: pramipexole clearance falls in proportion to declining CrCl, so a CrCl of 36 mL/min — well below normal — requires a reduced maximum daily dose rather than a return to the full preoperative regimen. His preoperative dose of 1 mg three times daily was appropriate for his preoperative CrCl of 54 mL/min; at a CrCl of 36 mL/min, a reduced dose set per the prescribing information, with careful upward retitration as renal function continues to improve, is required. Option C is correct.

• Option A: Option A is incorrect because removing the patch 24 hours before the first oral dose creates an unacceptable gap in dopaminergic therapy — approximately 24 hours without meaningful dopaminergic coverage — in a PD patient; acute motor deterioration and the risk of parkinsonism-hyperpyrexia syndrome make this approach unsafe. Additionally, a CrCl of 36 mL/min does require dose reduction, because pramipexole clearance falls with declining renal function.
• Option B: Option B is incorrect because leaving the rotigotine patch in place for 48 hours after starting oral pramipexole creates a prolonged period of double-dosing from both formulations simultaneously; pramipexole does not require days to achieve meaningful concentrations — immediate-release pramipexole reaches peak concentration within 1 to 3 hours.
• Option D: Option D is incorrect because removing the patch the night before creates a gap in dopaminergic coverage, and a CrCl of 36 mL/min does require dose adjustment — this level of renal impairment reduces pramipexole clearance and is not equivalent to normal renal function.
• Option E: Option E is incorrect because pre-dosing oral pramipexole 6 hours before patch removal would result in combined dopaminergic exposure from both agents during the 6-hour overlap, and pramipexole's plasma half-life of 8 to 12 hours does not require this pre-dosing strategy to achieve therapeutic concentrations; the simultaneous dose-and-remove approach is the correct method.

ANSWER: D

Rationale:

Impulse control disorders (ICDs) are a class-specific adverse effect of dopamine agonists, occurring in approximately 10 to 20% of patients on therapeutic doses. The mechanism is D3 receptor-mediated overactivation of the mesolimbic reward pathway. Ropinirole and pramipexole both have relatively high affinity for D3 receptors compared with D2 receptors, and D3 receptors are expressed at particularly high density in limbic structures — especially the nucleus accumbens and its connections to the prefrontal cortex — that regulate reward-seeking behavior. Overactivation of D3 receptors in this circuit sensitizes the reward system, lowering the threshold for compulsive, reward-driven behaviors and producing the spectrum of ICDs seen in this patient: pathological gambling and compulsive buying. The behaviors are not related to prior personality traits — they emerge de novo with agonist therapy and typically resolve with dose reduction. Option D is correct.

• Option A: Option A is incorrect because ropinirole does not have clinically significant serotonin reuptake inhibitor activity; it is a dopamine receptor agonist, and the ICD mechanism is dopaminergic D3 receptor overactivation, not serotonergic disinhibition of the prefrontal cortex.
• Option B: Option B is incorrect because D1 receptor activation in the dorsal striatum is related to motor function through the direct pathway, not to the limbic reward circuitry driving ICDs; the relevant receptor and anatomical location are D3 in the nucleus accumbens, not D1 in the dorsal striatum.
• Option C: Option C is incorrect because ropinirole does not have clinically significant histamine H1 receptor blocking activity — that profile characterizes first-generation antipsychotics and tricyclics — and hypothalamic histamine disruption is not the established mechanism of dopamine agonist-induced ICDs.
• Option E: Option E is incorrect because the ICD mechanism is postsynaptic D3 receptor overactivation in the limbic system, not presynaptic autoreceptor partial agonism reducing dopamine release feedback; the autoreceptor mechanism would actually predict reduced dopamine output, not increased.

ANSWER: B

Rationale:

When impulse control disorders cannot be managed through agonist dose reduction because the required reduction produces unacceptable motor deterioration, and the patient is unwilling to accept the functional decline, deep brain stimulation of the subthalamic nucleus represents the most pharmacologically rational advanced management strategy. DBS improves motor function through modulation of basal ganglia circuit activity via high-frequency electrical stimulation — a mechanism entirely independent of dopamine receptor occupancy. This motor improvement allows substantial postoperative reduction in dopaminergic medication, including the agonist dose, while maintaining adequate motor control. By reducing the agonist dose below the threshold for ICD-level D3 mesolimbic overactivation, DBS creates the pharmacological space for ICD resolution that dose reduction alone could not achieve. This approach is specifically recognized in movement disorder guidelines for refractory ICD in motor-dependent patients. Option B is correct.

• Option A: Option A is incorrect because the decision to accept motor impairment is the patient's to make with informed clinical guidance; overriding patient preference for motor function without exploring the available advanced therapeutic options — including DBS — is not appropriate management of a refractory clinical dilemma with established alternatives.
• Option C: Option C is incorrect because adding low-dose levodopa to partially substitute for ropinirole's motor benefit while reducing ropinirole is a reasonable adjunct strategy in some patients, but it has not been shown in controlled evidence to eliminate ICD behaviors at the ropinirole doses achievable with partial levodopa substitution; the degree of ropinirole reduction achievable this way may be insufficient to resolve ICDs.
• Option D: Option D is incorrect because switching to rotigotine at an equivalent total dopamine agonist dose does not reduce mesolimbic D3 overactivation sufficiently to eliminate ICDs — the D3-mediated ICD mechanism is driven by total D3 receptor stimulation from any agonist, not by ropinirole-specific pharmacology — and randomized trial evidence specifically showing ICD elimination with rotigotine switching without dose reduction does not exist.
• Option E: Option E is incorrect because naltrexone is not established as first-line pharmacotherapy for dopamine agonist-induced ICDs with the efficacy described; evidence for opioid antagonism in this setting is limited and does not support an 80% complete remission rate without dopaminergic therapy change.

ANSWER: E

Rationale:

This case illustrates the intersection of two pharmacological changes occurring simultaneously in the same patient. The patient was an active smoker whose CYP1A2 was continuously induced by polycyclic aromatic hydrocarbons in cigarette smoke, accelerating ropinirole metabolism and maintaining lower plasma concentrations than would be seen in a non-smoker at the same dose. When she quit smoking, the CYP1A2 induction gradually reversed over 1 to 4 weeks as the inducing compounds were cleared. As CYP1A2 activity returned toward uninduced baseline, ropinirole clearance slowed and plasma concentrations rose substantially at the dose that had been carefully selected for her post-DBS regimen. The result is ropinirole toxicity — nausea, dizziness, and somnolence — at an unchanged dose, purely from a pharmacokinetic change driven by smoking cessation. The management is ropinirole dose reduction to re-establish the plasma concentration appropriate for a non-smoker at her motor and ICD treatment requirements. Option E is correct.

• Option A: Option A is incorrect because nicotine withdrawal syndrome does not produce a dopaminergic surge that amplifies ropinirole's adverse effects pharmacodynamically; the mechanism is pharmacokinetic — rising ropinirole plasma concentrations — not a pharmacodynamic interaction with withdrawal physiology.
• Option B: Option B is incorrect because DBS electrode placement does not alter CYP enzyme expression in the striatum, and CYP enzyme activity relevant to drug metabolism is hepatic, not central; no synergistic interaction between DBS and smoking cessation on ropinirole metabolism has been established.
• Option C: Option C is incorrect because smoking cessation does not meaningfully reduce gastric acid secretion in a way that clinically increases ropinirole absorption; ropinirole's bioavailability is not significantly pH-dependent, and the pharmacokinetic interaction is entirely hepatic CYP1A2-mediated, not gastrointestinal.
• Option D: Option D is incorrect because the symptoms represent toxicity — excess drug effect — not deficiency; nicotine withdrawal does not cause D2 receptor upregulation sufficient to produce clinically significant ropinirole underdosing at the plasma concentrations achieved, and the described symptom complex of nausea, dizziness, and somnolence is consistent with drug excess, not depletion.

ANSWER: A

Rationale:

Visual hallucinations in Parkinson's disease patients on dopamine agonist therapy are most commonly drug-induced, reflecting dopaminergic overstimulation of mesolimbic and cortical pathways. In this patient, the temporal context — hallucinations emerging during agonist therapy — and the clinical features — insight preserved, no fever, no new medications, normal cognition — are consistent with drug-induced hallucinations rather than dementia-associated psychosis or infection-triggered delirium. The established management hierarchy is clear: the first step is dopamine agonist dose reduction or discontinuation, not the addition of an antipsychotic. Drug-induced hallucinations frequently resolve with dose reduction alone, and adding an antipsychotic without first reducing the causative agent leaves the pharmacological trigger in place while exposing the patient to additional medication risks. If hallucinations persist despite dose reduction, and if antipsychotic therapy is then needed, only quetiapine or clozapine are acceptable in PD. Option A is correct.

• Option B: Option B is incorrect because adding quetiapine before attempting dose reduction of the causative agent is not the first management step; dose reduction should be attempted first, and quetiapine is reserved for hallucinations that persist despite agonist reduction. The concern about ICD recurrence with dose reduction is valid but does not override the principle that drug-induced hallucinations should first be addressed by reducing the causative drug.
• Option C: Option C is incorrect because urgent brain MRI is not required before making a medication adjustment in a patient with a clear temporal relationship between agonist therapy and the emergence of typical drug-induced visual hallucinations with preserved insight; neuroimaging is indicated when there are clinical features suggesting a structural cause, which are absent here.
• Option D: Option D is incorrect because discontinuing all dopaminergic therapy is not indicated for mild, insight-preserved visual hallucinations; abrupt withdrawal of dopaminergic therapy risks acute motor deterioration and parkinsonism-hyperpyrexia syndrome, and the association between continued dopaminergic therapy and accelerated dementia progression is not established.
• Option E: Option E is incorrect because rivastigmine is used for cognitive decline and dementia in Parkinson's disease — it is not first-line management for drug-induced visual hallucinations in a cognitively intact patient; the appropriate first step is to reduce the causative agent.

ANSWER: C

Rationale:

Apomorphine cannot be given orally because it undergoes extensive and rapid first-pass hepatic metabolism. When absorbed from the gastrointestinal tract, apomorphine enters the portal circulation and is almost completely extracted and metabolized by the liver before reaching the systemic circulation, leaving negligible oral bioavailability. Subcutaneous injection delivers the drug directly into the systemic circulation via lymphatic and venous drainage from the subcutaneous tissue, bypassing the portal first-pass extraction entirely. This route achieves therapeutic plasma concentrations sufficient to activate D1, D2, D3, and D4 receptors in the striatum. The rapid subcutaneous absorption — peak plasma concentrations within 10 to 20 minutes — combined with the avoidance of first-pass metabolism makes the subcutaneous route pharmacokinetically ideal for acute rescue use. Option C is correct.

• Option A: Option A is incorrect because apomorphine's inability to be administered orally is not due to failure of intestinal absorption from molecular size or lack of transport proteins; the barrier is hepatic first-pass metabolism after absorption occurs, not the absorption step itself.
• Option B: Option B is incorrect because while apomorphine is susceptible to oxidation and requires careful storage, acid degradation in the stomach is not the primary pharmacokinetic barrier to oral use; first-pass hepatic metabolism is the established explanation for the negligible oral bioavailability.
• Option D: Option D is incorrect because intestinal sulfotransferase-mediated gut wall conjugation to inactive metabolites is not the established primary mechanism of apomorphine's poor oral bioavailability; the correct explanation is hepatic first-pass extraction, and while hepatic conjugation does contribute to apomorphine's systemic clearance and short half-life, the emphasis on gut wall sulfation as the primary barrier misidentifies the mechanism.
• Option E: Option E is incorrect because apomorphine is not characterized by extremely low lipid solubility preventing gastrointestinal absorption; it is sufficiently lipophilic to cross the blood-brain barrier effectively after parenteral administration, and the barrier to oral use is metabolic, not a physical absorption barrier related to lipid solubility differences between tissue compartments.

ANSWER: D

Rationale:

The co-administration of apomorphine with ondansetron, or with any other 5-HT3 antagonist, has been associated with profound hypotension and loss of consciousness in reported cases, and the combination is contraindicated. The contraindication rests on this observed clinical risk rather than on a fully established mechanism — the precise pharmacological basis has not been definitively characterized and should not be taught as settled. What is clinically actionable is clear: 5-HT3 antagonists as a class must not be used as antiemetics in patients receiving apomorphine, regardless of ondansetron's antiemetic efficacy in other settings. The correct protocol is domperidone 20 mg three times daily, started 3 days before the first apomorphine dose. Domperidone is a peripherally acting D2 antagonist that blocks dopamine receptors in the gut and chemoreceptor trigger zone without crossing the blood-brain barrier, providing effective antiemetic coverage without worsening motor function and without the risk that contraindicates 5-HT3 antagonists. Option D is correct.

• Option A: Option A is incorrect because ondansetron is not a CYP3A4 inhibitor to a clinically meaningful degree; it is metabolized by CYP3A4 and CYP1A2 but does not inhibit these enzymes significantly, and apomorphine accumulation through enzyme inhibition is not the mechanism of the contraindication.
• Option B: Option B is incorrect because ondansetron is a selective 5-HT3 antagonist with no clinically significant dopamine D2 receptor blocking activity; it does not worsen PD motor symptoms through D2 blockade, and this is not the basis of the contraindication.
• Option C: Option C is incorrect because ondansetron is not eliminated exclusively by renal excretion in elderly patients — it is hepatically metabolized — and accumulation-related QTc prolongation independent of the apomorphine interaction is not the primary mechanism of the contraindication.
• Option E: Option E is incorrect because nausea as a protective signal for apomorphine dose excess is not an established pharmacological concept, and eliminating this hypothetical signal is not the reason 5-HT3 antagonists are contraindicated; the contraindication rests on the observed risk of severe hypotension and loss of consciousness with the combination.

ANSWER: B

Rationale:

Subcutaneous skin nodules and indurations are the principal long-term limiting adverse effect of subcutaneous apomorphine use, developing in the majority of patients with prolonged therapy as cumulative subcutaneous trauma from repeated injections causes progressive fibrotic reactions at injection sites. These nodules are not an indication to permanently discontinue apomorphine, but rather a complication requiring active site management. The established approach is two-tiered: systematic rotation of injection sites across all available body areas to distribute trauma and delay the depletion of viable sites, combined with ultrasound-guided assessment to identify areas with adequate subcutaneous tissue depth and acceptable tissue quality. When nodule formation becomes so extensive that viable injection sites are exhausted despite these measures, levodopa-carbidopa intestinal gel delivered via a percutaneous endoscopic gastrojejunostomy tube provides the established alternative continuous dopaminergic delivery strategy, bypassing the subcutaneous tissue entirely. Option B is correct.

• Option A: Option A is incorrect because oral corticosteroids are not an established treatment for apomorphine-induced subcutaneous fibrotic nodules and would not reliably restore site viability; the fibrosis is a mechanical response to repeated tissue trauma rather than a steroid-responsive inflammatory process, and this approach is not a recognized management strategy.
• Option C: Option C is incorrect because subcutaneous nodule formation is a fibrotic site reaction, not a Coombs-positive hemolytic immune reaction; Coombs-positive hemolytic anemia is a separate and rare complication of long-term apomorphine use, distinct from the nodule complication, and the patient shows no features of hemolytic anemia.
• Option D: Option D is incorrect because alkalinizing the apomorphine solution with sodium bicarbonate is pharmacologically unsound — apomorphine requires an acidic pH for chemical stability, and alkalinization would degrade the drug; this approach is not an established clinical practice and would compromise drug efficacy.
• Option E: Option E is incorrect because diluting the apomorphine concentration to reduce local tissue drug concentration is not an established approach to nodule prevention or management; the nodules result from mechanical needle trauma rather than local drug concentration, and dilution would reduce the delivered apomorphine dose without addressing the underlying mechanical cause.

ANSWER: E

Rationale:

Continuous subcutaneous apomorphine infusion delivers apomorphine via a programmable pump over 12 to 16 waking hours, providing continuous dopaminergic stimulation that substantially reduces both off time and the required levodopa dose. Observational studies and prospective series have consistently reported reductions in off time of 50 to 70% and reductions in levodopa equivalent dose of 30 to 50% in patients successfully established on CSAI — outcomes that represent a meaningful and clinically significant improvement over optimized oral therapy alone. The principal long-term limiting adverse effect of CSAI is the development of skin nodules and subcutaneous indurations at infusion sites, which occurs in most patients with prolonged use. This is the same fundamental complication this patient has already experienced with intermittent injections, and it is important to counsel him that CSAI does not eliminate this risk — it manages it through systematic site rotation and ultrasound guidance at a continuous infusion rate. If CSAI site limitation eventually becomes prohibitive, LCIG remains the next escalation option. Option E is correct and adds the clinically important nuance that this patient's pre-existing nodule complication is directly relevant to CSAI candidacy and expectations.

• Option A: Option A is incorrect because the off-time reduction of 20 to 30% substantially understates the established efficacy of CSAI, and QTc prolongation requiring discontinuation in 30% of patients is not the principal long-term limiting adverse effect — skin nodules are.
• Option B: Option B is incorrect because CSAI reduces off time by approximately 50 to 70%, not 80 to 90%, and while it allows substantial levodopa dose reduction of 30 to 50%, it does not eliminate all concurrent oral levodopa in most patients; peripheral neuropathy as a direct neurotoxic effect of apomorphine infusion is not the established principal limiting adverse effect.
• Option C: Option C is incorrect as the best answer for this specific patient because it fails to acknowledge the critical clinical context that this patient has already experienced the principal limiting adverse effect — skin nodules — with intermittent injections, making this complication directly relevant to his CSAI candidacy and expectations; option E is the more complete and clinically appropriate answer for this specific patient.
• Option D: Option D is incorrect because CSAI does permit meaningful levodopa dose reduction of 30 to 50%; apomorphine's broad D1 and D2 receptor agonism produces sufficient dopaminergic effect to allow concurrent levodopa dose reduction, and this dose-sparing property is an established clinical advantage of CSAI.

ANSWER: A

Rationale:

The decision between levodopa and a dopamine agonist as initial therapy in Parkinson's disease is primarily governed by the patient's age and cognitive status. This patient presents with three converging factors that together clearly favor levodopa. First, at 80 years of age she is well above the approximately 70-year threshold above which the adverse effect profile of dopamine agonists — particularly cognitive worsening, excessive somnolence, confusion, impulse control disorders, and falls — is considered to outweigh the dyskinesia-delay benefit in most patients. Second, her pre-existing mild cognitive impairment (MoCA 22/30) represents significant cognitive vulnerability; dopamine agonists exacerbate cognitive impairment and cause confusion and hallucinations at substantially higher rates in patients with baseline cognitive deficits. Third, her independent living situation means that confusion, somnolence, or falls carry particularly serious consequences. Levodopa produces superior motor control and is much better tolerated cognitively in older patients with cognitive vulnerability — it is the appropriate initial agent. Option A is correct.

• Option B: Option B is incorrect because a CrCl of 38 mL/min does not make all non-ergot agonists contraindicated — ropinirole, for example, does not require renal dose adjustment since it is hepatically cleared, and rotigotine is also viable with caution; while pramipexole requires dose reduction at this CrCl, renal impairment alone does not make agonist-first therapy universally impractical.
• Option C: Option C is incorrect because agonist-first therapy has not been shown in randomized trials to accelerate cognitive decline specifically in patients over 75 or to be formally contraindicated in mild cognitive impairment; the preference for levodopa in this patient group is based on adverse effect risk-benefit assessment, not a formal contraindication established by trial evidence of accelerated cognitive decline.
• Option D: Option D is incorrect because the dyskinesia-delay benefit of agonist-first therapy is not limited to tremor-predominant PD and does not depend on the motor subtype — the benefit is related to the mechanism of continuous versus pulsatile receptor stimulation and applies across PD subtypes, not exclusively to tremor-predominant presentations.
• Option E: Option E is incorrect because not all dopamine agonists are renally eliminated; ropinirole is hepatically cleared and does not require renal adjustment, and the claim that agonist therapy is uniformly contraindicated in stage 3 CKD misrepresents the pharmacokinetic landscape of the non-ergot agonist class.

ANSWER: C

Rationale:

The distinction between pramipexole and ropinirole in the setting of renal impairment reflects their fundamentally different primary elimination pathways. Pramipexole is eliminated almost entirely by renal excretion as unchanged drug, with less than 10% undergoing hepatic metabolism. Its clearance is therefore directly proportional to creatinine clearance, so at a CrCl of 32 mL/min — well below normal — the maximum pramipexole dose must be reduced relative to the dose used at normal renal function, with the specific limit taken from the prescribing information. Ropinirole, by contrast, is cleared primarily by hepatic metabolism via CYP1A2. Renal excretion of unchanged ropinirole is not a meaningful elimination pathway, and renal function does not significantly affect its clearance. Ropinirole does not require dose adjustment for a CrCl of 32 mL/min and can be used at standard doses in this patient, provided hepatic function is adequate — making it the more straightforward agonist choice in this patient's clinical context. Option C is correct.

• Option A: Option A is incorrect because ropinirole is not cleared by renal tubular secretion as unchanged drug — this description applies to pramipexole; ropinirole's primary elimination is hepatic, making it independent of renal function and not subject to the same dose-adjustment requirements.
• Option B: Option B is incorrect because dose reduction for pramipexole in renal impairment is pharmacokinetically mandated by the patient's CrCl — it is a standard prescribing requirement, not a threshold at which drug levels must first be confirmed before adjusting; plasma concentration monitoring for pramipexole is not the standard approach to dose adjustment.
• Option D: Option D is incorrect because ropinirole does not produce active metabolites that accumulate in proportion to declining GFR; its metabolites are inactive conjugates, and its clearance is hepatic — renal function does not drive ropinirole dose adjustment; additionally, pramipexole does not undergo compensatory hepatic glucuronidation to a clinically meaningful degree that would offset reduced renal clearance.
• Option E: Option E is incorrect because neither pramipexole nor ropinirole is absolutely contraindicated at a CrCl of 32 mL/min — pramipexole can be used with mandatory dose reduction, and ropinirole requires no renal adjustment; rotigotine is also viable with caution in this patient, but the premise that the other two agents are categorically contraindicated is incorrect.

ANSWER: D

Rationale:

Visual hallucinations with partial or complete loss of insight in a PD patient on dopamine agonist therapy — particularly in a patient with pre-existing cognitive impairment who was already at elevated risk for agonist-induced cognitive adverse effects — are most likely drug-induced and require immediate dose reduction of the causative agent as the first intervention. The management hierarchy is clear: reduce or discontinue the agonist first, then reassess whether antipsychotic therapy is needed for hallucinations that persist despite dose reduction. This patient's pre-existing mild cognitive impairment was known to confer elevated ICD and cognitive risk from agonist therapy; the emergence of hallucinations with partial insight loss and cognitive decline after agonist initiation is temporally and mechanistically consistent with agonist-induced adverse effects. Levodopa can be adjusted to partially compensate for the reduction in agonist-driven motor benefit if needed. Option D is correct.

• Option A: Option A is incorrect because adding quetiapine without first attempting agonist dose reduction leaves the pharmacological trigger in place and adds a second psychoactive medication unnecessarily; the established hierarchy requires agonist dose reduction before antipsychotic addition.
• Option B: Option B is incorrect because this clinical scenario, while serious, does not require inpatient psychiatric admission before any outpatient pharmacological adjustment; drug-induced hallucinations in the context of a known causative agent are managed by reducing that agent, not by psychiatric hospitalization as the first step.
• Option C: Option C is incorrect because adding both rivastigmine and quetiapine simultaneously while maintaining ropinirole unchanged is not the correct first step; addressing the probable drug cause — the agonist — must precede polypharmacy addition, and rivastigmine is indicated for established PD dementia rather than as an acute antihallucinatory intervention.
• Option E: Option E is incorrect because ropinirole plasma level monitoring is not standard clinical practice for dose adjustment decisions; the indication for dose reduction is the clinical presentation of drug-induced adverse effects in a patient at elevated risk, not plasma concentration confirmation.

ANSWER: B

Rationale:

Risperidone — and virtually all antipsychotics other than quetiapine and clozapine — produce clinically significant striatal D2 receptor blockade at therapeutic doses. In Parkinson's disease, striatal D2 receptor activation by dopaminergic therapy is essential for motor function. D2 blockade by risperidone directly opposes this mechanism, causing severe acute worsening of parkinsonism — rigidity, akinesia, and tremor — that can be irreversible in some cases. The reasoning that "low-dose risperidone" minimizes this risk is incorrect; risperidone has among the highest D2 receptor affinity of any atypical antipsychotic, and even sub-milligram doses produce significant striatal D2 occupancy in PD patients. The acceptable antipsychotic options in PD are quetiapine — which has very low D2 receptor affinity at clinical doses and minimal striatal occupancy — and clozapine, which has the lowest D2 affinity of any antipsychotic. Pimavanserin, a selective 5-HT2A inverse agonist with no D2, D3, or D4 receptor activity, is also approved specifically for Parkinson's disease psychosis and avoids dopamine receptor blockade entirely. Option B is correct.

• Option A: Option A is incorrect because risperidone's contraindication in PD is based on striatal D2 receptor blockade worsening motor function, not on inhibition of renal tubular secretion affecting ropinirole levels; ropinirole is not renally eliminated, and this pharmacokinetic interaction does not exist.
• Option C: Option C is incorrect because risperidone's contraindication in PD is not based on anticholinergic properties — risperidone has relatively low anticholinergic activity compared with other antipsychotics — and haloperidol is among the most contraindicated agents in PD due to its extremely high D2 receptor affinity causing severe motor deterioration.
• Option D: Option D is incorrect because quetiapine and clozapine are not contraindicated in PD patients with cognitive impairment; while the black-box warning regarding antipsychotic use in dementia is relevant, it applies to all antipsychotics including the acceptable ones, and the clinical decision requires individualized risk-benefit assessment — it does not categorically prohibit quetiapine or clozapine use in PD with cognitive impairment.
• Option E: Option E is incorrect because risperidone is a 5-HT2A antagonist, not agonist; and the explanation of PD visual hallucinations as 5-HT2A overactivation requiring receptor blockade for treatment is an inversion of the actual pharmacology — pimavanserin works as a 5-HT2A inverse agonist precisely because 5-HT2A receptor activity contributes to hallucinations, not the other way around.

ANSWER: E

Rationale:

This patient's presentation — progressive exertional dyspnea and a new cardiac murmur in the context of 7 years of cabergoline therapy — is highly characteristic of cabergoline-induced fibrotic valvulopathy. Cabergoline, like pergolide, is an ergot-derived dopamine agonist that activates 5-HT2B receptors on cardiac valve interstitial fibroblasts. This receptor activation stimulates fibroblast proliferation and excess collagen deposition, producing a restrictive valvulopathy with regurgitation that is pathologically identical to the valve disease caused by fenfluramine and pergolide. The valvulopathy is dose-dependent and cumulative, meaning that risk increases with total cabergoline exposure over time — 7 years of therapy represents a substantial cumulative dose. Echocardiography is urgently required to characterize the valvular lesion, quantify the regurgitation, and guide further management. Option E is correct.

• Option A: Option A is incorrect because cabergoline does not have clinically significant alpha-adrenergic agonist activity causing hypertension — it is a dopamine receptor agonist with no established blood pressure-elevating mechanism — and his blood pressure is normal; the murmur and dyspnea in the context of cabergoline therapy require evaluation for valvulopathy.
• Option B: Option B is incorrect because while pleuropulmonary fibrosis is a recognized complication of ergot alkaloids, the primary and most clinically prominent fibrotic complication is cardiac valvulopathy, and a holosystolic murmur at the apex in this context indicates valvular regurgitation rather than pleural restriction.
• Option C: Option C is incorrect because Parkinson's disease autonomic neuropathy does not produce a holosystolic murmur; functional regurgitation from low cardiac output produces a softer, earlier murmur pattern, and attributing a grade 3/6 holosystolic murmur to functional causes without evaluating the structural valve disease risk in a patient on 7 years of cabergoline is clinically inadequate.
• Option D: Option D is incorrect because pericardial effusion does not produce a holosystolic murmur at the cardiac apex; pericardial effusion produces muffled heart sounds and possibly a friction rub, and D2 receptor-mediated pericardial fibroblast activation is not an established mechanism of cabergoline toxicity.

ANSWER: A

Rationale:

The echocardiographic findings confirm cabergoline-induced fibrotic valvulopathy — the drug is the causative agent and must be discontinued. Continued cabergoline exposure perpetuates 5-HT2B receptor activation on valve interstitial fibroblasts, driving ongoing fibroblast proliferation and collagen deposition. While established fibrosis does not fully reverse after discontinuation, halting further drug exposure prevents additional progression and allows some degree of stabilization. The patient must be transitioned to a non-ergot dopamine agonist. Pramipexole and ropinirole are the standard non-ergot alternatives; both lack 5-HT2B receptor activity and do not carry a valvulopathy risk, making either appropriate for the transition. The cardiologist should remain involved for ongoing surveillance of the established valvular lesion. Option A is correct.

• Option B: Option B is incorrect because there is no established dose threshold below which cabergoline's valvulopathy risk is eliminated, and no evidence that reducing the dose allows regression of established fibrotic valve changes; the appropriate action is discontinuation and transition, not dose reduction with continued exposure.
• Option C: Option C is incorrect because immediate surgical valve repair or replacement is not required for moderate regurgitation with preserved systolic function in the absence of severe symptoms; while ongoing cardiac follow-up is required, surgery is not mandated at this stage, and drug discontinuation is the immediate priority.
• Option D: Option D is incorrect because the presence of a known causative agent producing progressive fibrotic valvulopathy does mandate drug discontinuation, even in the absence of severe symptoms; continuing cabergoline with only serial echocardiography allows the causative drug to drive further valve damage.
• Option E: Option E is incorrect because bromocriptine is also an ergot agonist with 5-HT2B receptor activity, and while its affinity may be lower than cabergoline's, it still carries a valvulopathy risk; bromocriptine is not the appropriate transitional agent for a patient with established ergot-induced valve disease — non-ergot agonists are the correct class.

ANSWER: C

Rationale:

Pramipexole is eliminated almost entirely by renal excretion as unchanged drug, and its clearance falls in proportion to declining creatinine clearance. A CrCl of 42 mL/min is well below normal, so the maximum daily dose that can be given safely is reduced relative to the dose appropriate for normal renal function. The drug can still be used in this patient, but it should be initiated at a low starting dose and titrated upward carefully without exceeding the reduced ceiling indicated for his CrCl in the prescribing information. Renal function should be monitored during therapy, particularly as the patient ages or if other factors affecting renal function intervene. Option C is correct.

• Option A: Option A is incorrect because pramipexole clearance is not independent of renal function — it is directly proportional to CrCl; a value of 42 mL/min represents meaningful renal impairment requiring a reduced maximum dose, and describing this range as clinically normal for drug dosing is incorrect and potentially harmful.
• Option B: Option B is incorrect because a CrCl of 42 mL/min is not an absolute contraindication to pramipexole; the drug can be used with appropriate dose reduction at this level of renal function, and contraindication would apply only if no safe dose could be administered, which is not the case here.
• Option D: Option D is incorrect because pramipexole dose adjustment in renal impairment is driven by CrCl, not by a combined formula incorporating age and weight; the prescribing information does not specify a fixed additional age-based reduction layered on top of the renal adjustment.
• Option E: Option E is incorrect because starting at the lowest dose does not by itself protect against accumulation when renal clearance is reduced; the maximum daily dose that can be reached safely is lowered in renal impairment, so the ceiling on titration — not only the starting dose — must be reduced according to his CrCl.

ANSWER: D

Rationale:

Peripheral edema is a recognized class adverse effect of dopamine agonists, occurring in approximately 10 to 15% of patients on these agents. The mechanism reflects dopamine receptor-mediated peripheral vasodilation and altered capillary permeability, causing fluid to shift from the intravascular space into subcutaneous tissues — particularly the dependent lower extremities. The edema is not mediated by sodium and water retention in the conventional diuretic-responsive sense, which is why diuretics are generally not effective and are not recommended as the primary management strategy. The correct first intervention is pramipexole dose reduction, which addresses the pharmacological cause of the fluid shift and typically leads to resolution or substantial improvement of the edema. Option D is correct.

• Option A: Option A is incorrect because the echocardiography confirms stable mitral regurgitation without progression, and bilateral ankle edema appearing after pramipexole initiation in the absence of functional worsening is most appropriately attributed to the known agonist class adverse effect rather than subclinical cardiac decompensation; empirical furosemide without addressing the pharmacological cause is not the first-line approach.
• Option B: Option B is incorrect because pramipexole does not cause peripheral edema through D2-mediated antidiuretic hormone-like sodium and water retention in the renal collecting duct; the mechanism is peripheral vascular rather than renal tubular, and thiazide diuretics are not effective for this type of edema.
• Option C: Option C is incorrect because a Coombs-positive immune reaction involving pramipexole metabolites causing peripheral edema is not an established adverse effect of pramipexole; Coombs-positive hemolytic anemia is a recognized complication of apomorphine infusion, not of oral pramipexole, and the presentation is not consistent with an immune hemolytic process.
• Option E: Option E is incorrect because pramipexole does not inhibit renal prostaglandin synthesis; this mechanism characterizes NSAIDs, and aspirin would have no pharmacological basis for treating dopamine agonist-induced peripheral edema.

ANSWER: B

Rationale:

Dopamine dysregulation syndrome is a compulsive overuse of dopaminergic medications — most commonly levodopa — driven by the hedonic and stimulant-like effects of supraphysiological dopaminergic activity in the mesolimbic reward system. Patients take medication far in excess of what motor control requires, resist dose reduction against medical advice, and continue despite objective clinical harm. DDS is distinguished from inadequate prescribing by the clinical findings at the self-administered dose: in an underprescribed patient, taking a higher dose produces motor improvement — the dose is genuinely insufficient for adequate motor control. In DDS, the self-administered excess dose produces dyskinesias and objectively worsened motor function — the dose is supraoptimal, and the mesolimbic hedonic drive sustains the compulsive overuse despite this harm. This patient has severe dyskinesias, objectively worsened motor function at 2,000 mg, and was more functional at a lower dose — all confirming pharmacological excess, not deficiency. His history of alcohol dependence, young onset PD, and male sex are all established DDS risk factors. Option B is correct.

• Option A: Option A is incorrect because D2 receptor downregulation causing levodopa tolerance is not the established mechanism of DDS; the clinical picture — compulsive self-escalation with objective harm — is not explained by tolerance, and increasing the prescribed dose to match his self-selected level would worsen his clinical state and reinforce the compulsive behavior.
• Option C: Option C is incorrect because the objective clinical findings — severe dyskinesias and worsened motor function — confirm that he is taking excess medication causing harm; factitious disorder does not explain severe dyskinesias in a patient on an insufficient dose.
• Option D: Option D is incorrect because while genetic factors can influence dyskinesia susceptibility, rapid-onset levodopa dyskinesias from a dopamine transporter gene variant is not an established clinical entity, and the clinical context — compulsive self-escalation with objective deterioration — is fully explained by DDS without invoking a genetic mechanism.
• Option E: Option E is incorrect because DDS does not require a formal neuropsychological battery or prospective documentation over 3 months for diagnosis; the clinical findings of compulsive self-escalation against medical advice, dose-related objective harm (dyskinesias, motor deterioration), and the presence of established risk factors are sufficient for clinical diagnosis and require prompt management.

ANSWER: E

Rationale:

The established risk factors for dopamine dysregulation syndrome include young onset of Parkinson's disease, male sex, a personal history of substance misuse or alcohol dependence, impulsive personality traits, and depression — a profile that reflects underlying mesolimbic reward pathway vulnerability. This patient has three of these factors: young-onset PD (diagnosed at age 42), male sex, and a history of alcohol dependence in remission. Critically, this risk profile is virtually identical to that for impulse control disorders, which are also driven by mesolimbic D3 receptor overactivation sensitizing the reward pathway. The shared pathophysiology explains why the two syndromes have overlapping risk factors and frequently co-exist in the same patient — a patient with DDS may simultaneously develop pathological gambling, hypersexuality, or compulsive shopping (ICD), because both result from dopaminergic overactivation of the same limbic reward circuitry. The distinction between them is behavioral: in DDS, the compulsive behavior targets the dopaminergic medications themselves, while in ICD it targets external reward activities. Option E is correct.

• Option A: Option A is incorrect because DDS risk is not determined exclusively by cumulative drug exposure — patient demographic and psychiatric characteristics are independently predictive risk factors; the alcohol history and young onset PD are specifically established as risk factors in published literature.
• Option B: Option B is incorrect because while male sex and substance use history are validated DDS risk factors, young-onset PD is also an established independent risk factor in the DDS literature; confining the validated factors to only two misrepresents the evidence base.
• Option C: Option C is incorrect because online access to medications is not an established biological risk factor for DDS — it may facilitate the behavior, but the underlying vulnerability is neurobiological, reflecting mesolimbic reward pathway sensitivity; framing DDS as primarily environmentally driven misidentifies its pathophysiology.
• Option D: Option D is incorrect because DDS and ICD are not mutually exclusive — they share overlapping risk factors and frequently co-exist; the claim that DDS occurs only in patients with substance histories while ICD occurs only in those without is factually incorrect and contradicts the established clinical observation that both syndromes can occur together.

ANSWER: A

Rationale:

Dopamine dysregulation syndrome shares the neurobiological substrate of substance addiction — both involve pathological sensitization of the mesolimbic reward pathway producing compulsive behavior that the individual cannot control through willpower alone. In DDS, the compulsive behavior targets the dopaminergic medications themselves, and the patient's relationship with levodopa is analogous to an addicted patient's relationship with their substance of misuse. Simply informing the patient of the correct dose and rewriting the prescription is insufficient because it does not address the neurobiological drive sustaining the behavior. The appropriate management framework requires three components: a structured, gradual dose-reduction program (abrupt reduction risks severe motor deterioration and potentially parkinsonism-hyperpyrexia syndrome), behavioral support to address the compulsive relationship with the medication, and psychiatric co-management — particularly important in this patient given his history of alcohol dependence, which reflects pre-existing reward pathway vulnerability that will complicate the dose-reduction process. Option A is correct.

• Option B: Option B is incorrect because DDS does not require inpatient detoxification with abrupt levodopa discontinuation; abrupt withdrawal of levodopa is dangerous and risks parkinsonism-hyperpyrexia syndrome, and clonidine is not established as a treatment for dopaminergic withdrawal in DDS; the management is structured gradual dose reduction, not abrupt cessation.
• Option C: Option C is incorrect because DDS is not comparable to a simple prescribing error, and patients with DDS do not have intact voluntary control over their medication use — the compulsive overuse is neurobiologically driven and does not reliably respond to information and instruction alone; behavioral and psychiatric support are essential components of management.
• Option D: Option D is incorrect because haloperidol is contraindicated in Parkinson's disease due to its potent central D2 receptor blockade causing severe motor deterioration; using it to interrupt mesolimbic reward signaling in DDS would produce unacceptable motor harm and is not an established or appropriate approach.
• Option E: Option E is incorrect because DDS is not irreversible — structured dose reduction with behavioral support can successfully bring medication use to therapeutic levels and reduce the compulsive behavior, even in patients with prior substance use history; supervised dispensing is a useful adjunct but not the limit of achievable management.

ANSWER: C

Rationale:

DDS and ICD share a common pathophysiological substrate: sensitization of the mesolimbic dopaminergic reward pathway, particularly through D3 receptor overactivation in the nucleus accumbens and its connections to the prefrontal cortex. In DDS, the compulsive behavior targets the dopaminergic medications themselves — the patient compulsively seeks and consumes levodopa and pramipexole driven by their hedonic and stimulant-like effects in the mesolimbic system. In ICD, the sensitized reward pathway drives compulsive engagement in external reward activities — gambling and hypersexuality in this patient — through D3-mediated lowering of the reward threshold. The co-existence of both syndromes in this patient reflects the extreme degree of mesolimbic overactivation from his combined levodopa excess and pramipexole's high D3 receptor affinity. Because both syndromes arise from the same overactivated pathway, reducing total dopaminergic burden — bringing both levodopa and pramipexole toward therapeutic doses through a structured reduction program — targets both syndromes simultaneously, reducing mesolimbic D3 overactivation that drives both the medication craving of DDS and the external reward-seeking of ICD. Behavioral and psychiatric support addresses the co-occurring compulsive behaviors as the pharmacological burden is reduced. Option C is correct.

• Option A: Option A is incorrect because DDS and ICD do not involve opposite receptor regulatory states and are not mutually exclusive; they share the same pathophysiological mechanism — mesolimbic reward pathway sensitization — and frequently co-exist in the same patient, as established in the clinical literature.
• Option B: Option B is incorrect because DDS is not caused by D1 receptor overactivation from levodopa as distinct from D3-mediated ICD from pramipexole; both syndromes reflect mesolimbic dopaminergic overactivation through shared circuitry, and the management requires reducing total dopaminergic burden, not eliminating one drug while maintaining the other.
• Option D: Option D is incorrect because naltrexone and SSRIs are not established sequential first-line treatments for DDS and ICD respectively; the primary intervention is reducing the total dopaminergic burden driving both syndromes, with behavioral and psychiatric support as adjuncts; deferring dopaminergic medication changes until behavioral syndromes are pharmacologically stabilized inverts the correct treatment priority.
• Option E: Option E is incorrect because the gambling and hypersexuality in this patient are drug-induced — they began temporally concurrent with his dopaminergic dose escalation in a patient without prior ICD behaviors, and they represent recognized adverse effects of dopamine agonist therapy in a patient with D3-mediated reward pathway sensitization; attributing them solely to a pre-existing addictive character trait and excluding them from neurological management ignores their established pharmacological etiology.